Newsroom
Sorted by: Latest
-
Deutsche Bank AG UK Regulatory Announcement: Issuance of Securities
LONDON--(BUSINESS WIRE)-- DB ETC PLC Dated: 28 July 2026 COMPANY ANNOUNCEMENT Immediate Release 28 July 2026 DB ETC plc (the Issuer) Law 1991 (as amended) with registered number 103781) Re: Issuance of ETC Securities Announcement The Issuer has agreed to issue ETC Securities for the following Series as set out in the table below. Series Tranche Number of Securities to be issued Trade Date Settlement Date ISIN: Series 10 - Xtrackers Physical Silver ETC (EUR) 459 2,600 24 July 2026 28 July 202...
-
Northern Trust Expands U.S. Fund Servicing Capabilities with ETF Platform Launch
CHICAGO--(BUSINESS WIRE)--Northern Trust has launched its U.S. exchange-traded fund (ETF) servicing platform with its appointment to support a new ETF by Harding Loevner....
-
Lallemand Biofuels & Distilled Spirits and Braskem Announce Bio-Acetone as a Coproduction Opportunity in Ethanol Facilities
MONTREAL & PHILADELPHIA--(BUSINESS WIRE)--Lallemand Biofuels & Distilled Spirits (LBDS), a global leader in yeast, enzymes, microbials and nutrition, and Braskem (B3: BRKM3, BRKM5, and BRKM6; NYSE: BAK; LATIBEX: XBRK), the largest polyolefins producer in the Americas and global leader in the production of biopolymers on an industrial scale, today announced an innovative bio-acetone production platform for the corn-ethanol industry that enables producers to generate a new coproduct alongside...
-
Kara Raiguel, John J. Marchioni, and Susan Rivera Named Chair and Vice Chairs of The Institutes Board of Trustees
MALVERN, Pa.--(BUSINESS WIRE)--The Institutes announced its Board of Trustees will be led by the CEOs of Gen Re, Selective Insurance Group and Tokio Marine HCC....
-
Charles Schwab Investment Management, Inc. UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Charles Schwab Investment Management, Inc. (CSIM) in its capacity as investment advisor to clients. CSIM expressly disclaims beneficial ownership of the shares described in this form 8.3. (b) Owner or controller of interests and short positions...
-
Argonne’s AI transformers to improve nuclear reactor simulations
LEMONT, Ill.--(BUSINESS WIRE)--AI transformers model complex physical systems and improve fluid-dynamics simulations for advanced nuclear reactors....
-
Grindr for Equality zobowiązuje się zapewnić, aby do 2028 r. informacje na temat usług w zakresie profilaktyki HIV dotarły do 10 mln osób
RIO DE JANEIRO--(BUSINESS WIRE)--Dziś podczas Międzynarodowej Konferencji AIDS 2026 inicjatywa Grindr for Equality zobowiązała się do zapewnienia, aby do 2028 r. informacje na temat profilaktyki HIV dotarły do dziesięciu milionów osób LGBTQ+, wykorzystując w tym celu zasięg swojej platformy, aby wesprzeć globalne wysiłki na rzecz wyeliminowania HIV do 2030 r. Zobowiązanie to jest wynikiem ustaleń nowego raportu inicjatywy Grindr for Equality pt. Closing the Gap [Wyeliminować lukę], który opisuj...
-
ADTN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into ADTRAN Holdings (ADTN)
NEW YORK--(BUSINESS WIRE)--ADTRAN Holdings (NASDAQ: ADTN) shares fell approximately 15% on July 22, 2026 after the company announced preliminary unaudited Q2 2026 revenue of $280 million to $282 million and non-GAAP operating margin of about 3.5% to 4.0%, both below its guidance of $283 million to $303 million in revenue and 5% to 9% non-GAAP operating margin. If this decline hit your ADTN investment, you are encouraged to submit your information now. You may also contact Joseph E. Levi, Esq. a...
-
REEV Launches Pivotal Clinical Study of DREEVEN for Post-Stroke Mobility
BOSTON--(BUSINESS WIRE)--REEV launches its pivotal clinical study of the DREEVEN robotic knee brace in post-stroke mobility in clinical and home settings....
-
RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy’s Laboratories (RDY)
NEW YORK--(BUSINESS WIRE)--RDY shareholders saw Dr. Reddy’s Laboratories (NYSE: RDY) shares fall approximately 9% on July 22, 2026, after Q1 FY27 results included a ₹2.4 billion provision tied to out-of-spec semaglutide batches while FY27 margin commentary remained in focus. Investors who lost money on RDY after that provision disclosure are encouraged to act now. Levi & Korsinsky is investigating potential securities law violations involving Dr. Reddy’s forward-looking profitability stateme...